KR0163371B1 - 5-아릴인돌 유도체 - Google Patents

5-아릴인돌 유도체 Download PDF

Info

Publication number
KR0163371B1
KR0163371B1 KR1019950701729A KR19950701729A KR0163371B1 KR 0163371 B1 KR0163371 B1 KR 0163371B1 KR 1019950701729 A KR1019950701729 A KR 1019950701729A KR 19950701729 A KR19950701729 A KR 19950701729A KR 0163371 B1 KR0163371 B1 KR 0163371B1
Authority
KR
South Korea
Prior art keywords
ylmethyl
indol
benzimidazole
methylpyrrolidin
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019950701729A
Other languages
English (en)
Korean (ko)
Other versions
KR950704313A (ko
Inventor
존 유진 마코
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR950704313A publication Critical patent/KR950704313A/ko
Application granted granted Critical
Publication of KR0163371B1 publication Critical patent/KR0163371B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1019950701729A 1992-11-02 1993-10-19 5-아릴인돌 유도체 Expired - Fee Related KR0163371B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
US7/970,758 1992-11-02
PCT/US1993/009790 WO1994010171A1 (en) 1992-11-02 1993-10-19 5-arylindole derivatives and their use as serotonin (5-ht1) agonists

Publications (2)

Publication Number Publication Date
KR950704313A KR950704313A (ko) 1995-11-17
KR0163371B1 true KR0163371B1 (ko) 1998-12-01

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701729A Expired - Fee Related KR0163371B1 (ko) 1992-11-02 1993-10-19 5-아릴인돌 유도체

Country Status (27)

Country Link
US (1) US5886008A (enExample)
EP (2) EP0666858B1 (enExample)
JP (1) JP2788551B2 (enExample)
KR (1) KR0163371B1 (enExample)
CN (1) CN1051313C (enExample)
AT (1) ATE202102T1 (enExample)
AU (1) AU685066B2 (enExample)
BR (1) BR9307348A (enExample)
CA (2) CA2340999C (enExample)
CZ (1) CZ283001B6 (enExample)
DE (1) DE69330351T2 (enExample)
DK (1) DK0666858T3 (enExample)
EG (1) EG20396A (enExample)
ES (1) ES2157224T3 (enExample)
FI (2) FI111257B (enExample)
GR (1) GR3036579T3 (enExample)
HU (1) HU222235B1 (enExample)
IL (1) IL107386A (enExample)
MY (1) MY109696A (enExample)
NO (1) NO309652B1 (enExample)
NZ (1) NZ257059A (enExample)
PL (1) PL176091B1 (enExample)
PT (1) PT666858E (enExample)
RU (1) RU2134266C1 (enExample)
TW (1) TW251284B (enExample)
WO (1) WO1994010171A1 (enExample)
ZA (1) ZA938137B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
AU685881B2 (en) * 1994-02-10 1998-01-29 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
EP0994877A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6353008B1 (en) * 1998-06-30 2002-03-05 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
RU2006108799A (ru) * 2003-08-21 2006-07-27 Оси Фармасьютикалз, Инк. (Us) N3-замещенные имидазопиридиновые ингибиторы c-kit
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
BRPI0709077A2 (pt) * 2006-03-22 2012-04-10 Janssen Pharmaceutica Nv derivados de alquilaminas cìclicas como inibidores da interação entre mdm2 e p53
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
CA2984290C (en) 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
JP6800885B2 (ja) 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
ES2865330T3 (es) * 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
CA3002489C (en) 2015-11-06 2023-11-07 F.Hoffmann-La Roche Ag Indolin-2-one derivatives
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
EP0636623B1 (en) * 1990-06-07 2001-08-16 AstraZeneca AB Indole derivatives as 5-HT1- like agonists
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
DE9190141U1 (de) * 1990-10-15 1993-07-15 Pfizer Inc., New York, N.Y. Indolderivate
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
CN1094727A (zh) 1994-11-09
CZ110895A3 (en) 1995-11-15
JPH07508759A (ja) 1995-09-28
AU685066B2 (en) 1998-01-15
ES2157224T3 (es) 2001-08-16
HUT66011A (en) 1994-08-29
ZA938137B (en) 1995-05-02
CA2340999A1 (en) 1994-05-11
NO951633L (no) 1995-04-28
EG20396A (en) 1999-02-28
CN1051313C (zh) 2000-04-12
KR950704313A (ko) 1995-11-17
DE69330351D1 (de) 2001-07-19
EP0666858A1 (en) 1995-08-16
NO309652B1 (no) 2001-03-05
WO1994010171A1 (en) 1994-05-11
US5886008A (en) 1999-03-23
FI111257B (fi) 2003-06-30
PL308669A1 (en) 1995-08-21
JP2788551B2 (ja) 1998-08-20
CZ283001B6 (cs) 1997-12-17
CA2148380A1 (en) 1994-05-11
GR3036579T3 (en) 2001-12-31
CA2148380C (en) 2001-08-14
DK0666858T3 (da) 2001-08-27
ATE202102T1 (de) 2001-06-15
HU222235B1 (hu) 2003-05-28
EP1094064A1 (en) 2001-04-25
NO951633D0 (no) 1995-04-28
PT666858E (pt) 2001-09-28
MY109696A (en) 1997-04-30
EP0666858B1 (en) 2001-06-13
AU5329494A (en) 1994-05-24
DE69330351T2 (de) 2001-09-20
FI20002505L (fi) 2000-11-15
RU95109927A (ru) 1997-01-10
IL107386A (en) 1999-03-12
FI934825L (fi) 1994-05-03
FI934825A0 (fi) 1993-11-01
PL176091B1 (pl) 1999-04-30
FI20002505A7 (fi) 2000-11-15
IL107386A0 (en) 1994-01-25
TW251284B (enExample) 1995-07-11
NZ257059A (en) 1997-07-27
RU2134266C1 (ru) 1999-08-10
CA2340999C (en) 2005-01-04
BR9307348A (pt) 1999-05-11

Similar Documents

Publication Publication Date Title
KR0163371B1 (ko) 5-아릴인돌 유도체
AU671959B2 (en) Indole derivatives
CN107406426B (zh) 作为rock抑制剂的环状脲类
FI101224B (fi) Menetelmä terapeuttisesti käyttökelpoisten alkoksipyrimidiinijohdannai sten valmistamiseksi
KR0179073B1 (ko) 5-ht1 작용물질로서의 인돌 유도체
KR19990072101A (ko) 고나도트로핀 분비 호르몬의 길항제
EP0548813A1 (en) Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
US5498626A (en) Acylaminoindole derivatives as 5-ht1 agonists
MXPA05003817A (es) Derivados de azaindoles como inhibidores de p38 quinasa.
NZ228721A (en) Substituted indoles and indazoles and pharmaceutical compositions
WO2021263278A1 (en) Rev-erb agonists for the treatment of th17-mediated inflammatory disorders
CN120769853A (zh) 用于靶向tp53-y220c突变体的化合物和组合物
AU673098B2 (en) Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
WO2006112828A1 (en) Azaindole derivatives as inhibitors of p38 kinase
WO1998042710A1 (fr) Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
TW202515569A (zh) 雙環及單環trpa1抑制劑

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20020809

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030906

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030906

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000